ZS Pharma Reports Fourth Quarter and Year-End 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ZS Pharma Reports Fourth Quarter and Year-End 2014 Financial Results and Provides ZS-9 Program Update

REDWOOD CITY, Calif., March 13, 2015 (GLOBE NEWSWIRE) -- ZS Pharma, Inc. (Nasdaq: ZSPH ), a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders, today provided a program update on ZS-9 (sodium zirconium cyclosilicate), the Company's investigational treatment for hyperkalemia, and reported its financial results for the fourth quarter and year ended December 31, 2014.

"We made significant progress with ZS-9 last year including the publication of our Phase 3 trials in JAMA and NEJM highlighting the interest from the medical community in hyperkalemia and in ZS-9," said Robert Alexander, Ph.D., chief executive officer of ZS Pharma. "As we approach the submission of our NDA in the second quarter of this year, we believe that we have the most robust and comprehensive clinical trial program addressing acute and chronic hyperkalemia."

Recent Highlights

  • We held a positive pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) regarding ZS-9. The FDA informed the Company that it does not plan at this time to conduct an advisory committee meeting to review ZS-9;
     
  • Patients are entering their eleventh month of treatment in our long-term trials which are designed to evaluate the ability of ZS-9 to restore and maintain normal serum potassium levels in patients with hyperkalemia;
     
  • We expanded the commercial organization with key executive hires from Genentech, Sanofi/Genzyme and Amgen in sales, marketing and medical affairs;
     
  • We presented detailed results from HARMONIZE (ZS004), the second Phase 3 trial of ZS-9, at the American Heart Association (AHA) Scientific Meeting with simultaneous publication in The Journal of the American Medical Association (JAMA) on November 17, 2014;
     
  • We published results from the first Phase 3 trial, ZS003, in the New England Journal of Medicine (NEJM) on November 21, 2014; and
     
  • We appointed Martin Babler to the ZS Pharma Board of Directors, bringing significant commercialization experience to the Board.

Upcoming 2015 Milestones

  • File the ZS-9 NDA with the FDA in the second quarter of 2015;
  • File the ZS-9 Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the second half of 2015; and
  • Present ZS-9 clinical trial results at the American College of Cardiology Annual Scientific Session and the National Kidney Foundation Spring Clinical Meeting.

Fourth Quarter and Year-End 2014 Financial Results

Research and development expenses for the quarter and year ended December 31, 2014, were $14.6 million and $45.6 million, respectively, compared with research and development expenses of $6.9 million and $24.8 million, respectively, for the same periods in 2013. The increase in research and development expenses was primarily due to increased personnel costs and costs associated with the enrollment and completion of ZS004 (HARMONIZE), the initiation of ZS004E (HARMONIZE Extension study), the increased rate of enrollment in ZS005 (long-term safety study) during the quarter and costs related to the continuing manufacturing scale-up of ZS-9.

General and administrative expenses for the quarter and year ended December 31, 2014, were $5.5 million and $14.9 million, respectively, compared with general and administrative expenses of $3.5 million and $7.4 million, respectively, for the same periods in 2013. The increase in general and administrative expenses was primarily due to an increase in compensation, professional fees and other expenses to support the Company's expanding operations, including increased spend in medical education programs; and the increased complexities of operating as a public company.

ZS Pharma reported net loss attributable to common shareholders of $20.3 million, or $0.98 per diluted share, for the quarter ended December 31, 2014, compared with a net loss attributable to common shareholders of $11.8 million, or $7.38 per diluted share, for the same period in 2013. ZS Pharma reported net loss attributable to common shareholders of $64.4 million, or $5.47 per diluted share, for the full year 2014, compared with a net loss attributable to common shareholders of $34.3 million, or $21.84 per diluted share, for the full year 2013.

At December 31, 2014, cash, cash equivalents and short-term investments totaled $102.3 million, compared with $9.2 million at December 31, 2013.

ZS Pharma had approximately 20.9 million shares outstanding as of December 31, 2014.

About ZS Pharma

ZS Pharma is a publicly-traded (Nasdaq: ZSPH ), biopharmaceutical company with offices in Redwood City, California and Coppell, Texas. ZS Pharma's lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. ZS Pharma is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases. Additional information about ZS Pharma is available at www.zspharma.com .

Forward-Looking Statements

ZS Pharma cautions you that this press release contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our expectations regarding the timing of submitting an NDA to the FDA and MAA to the EMA and the likelihood of regulatory approval of ZS-9, our expectations regarding our ability to successfully commercialize ZS-9, if approved, estimates of our expenses, future revenue, capital requirements and needs for additional financing, our ability to produce ZS-9 in commercial quantities in higher capacity reactors, the initiation, timing, progress and results of future nonclinical studies, clinical trials and research and development programs, and our financial performance. Any forward looking statements in this press release are based on management's current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that may cause actual results to differ materially from expectations include, among other things, those listed under Part I, Item 1A. Risk Factors in ZS Pharma's Annual Report on Form 10-K filed with the Securities and Exchange Commission March 13, 2015 and its other reports, which are available from the SEC's website ( http://www.sec.gov ) and on ZS Pharma's website ( http://www.zspharma.com ) under the heading "Investors". All forward‐looking statements are qualified in their entirety by this cautionary statement and speak only as of the date of this press release. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks described in the reports we will file from time to time with the SEC after the date of this press release.

ZS Pharma, Inc.
Condensed Statements of Operations
(Unaudited)
(In Thousands, Except for Share and Per Share Amounts)
 
  Three Months
Ended
December 31
2014
Three Months
Ended
December 31
2013
Year Ended
December 31
2014
Year Ended
December 31
2013
         
Costs and expenses        
Research and development  $ 14,574  $ 6,880  $ 45,618  $ 24,762
General and administrative  5,535  3,521  14,919  7,432
   20,109  10,401  60,537  32,194
Loss from operations  (20,109)  (10,401)  (60,537)  (32,194)
Other (income) expense:        
Interest/other income  (43)  (5)  (94)  (30)
Interest expense  249  (4)  530  9
Expense to mark warrants to market  --   1,272  3,071  1,424
Net loss  (20,315)  (11,664)  (64,044)  (33,597)
Preferred stock accretion  --   (174)  (310)  (689)
Net loss attributable to common shareholders  $ (20,315)  $ (11,838)  $ (64,354)  $ (34,286)
         
Net loss per share attributable to common shareholders, basic and diluted  $ (0.98)  $ (7.38)  $ (5.47)  $ (21.84)
         
Weighted-average common shares used to compute net loss per share attributable to common shareholders, basic and diluted  20,832,475  1,604,490  11,768,267  1,569,583
         
ZS Pharma, Inc.
Condensed Balance Sheet Data
(In Thousands)
 
  December 31
2014
December 31
2013
     
Cash, cash equivalents and short-term investments  $ 102,280  $ 9,170
     
Working capital  $ 94,117  $ 4,571
     
Total assets  $ 116,162  $ 14,046
     
Accumulated deficit  $ (114,278)  $ (50,234)
     
Total shareholders' equity (deficit)  $ 96,772  $ (45,182)

ZS Pharma Contacts Adam Tomasi (Investors) ZS Pharma 650.458.4100 Denise Powell (Media) Red House Consulting 510.703.9491

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 107

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 128

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 82

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading